New York, New York (PRWEB) January 16, 2014
Byetta lawsuits (http://www.byettalawsuit.com), as well as product liability claims involving other incretin mimetic diabetes drugs, continue to mount in the federal multidistrict litigation now underway in U.S. District Court, Southern District of California, Bernstein Liebhard LLP reports. According to an update issued by the U.S. Judicial Panel on Multidistrict Litigation (JPML) on January 15, 2014, at least 262 lawsuits that allege an association between drugs like Byetta and pancreatic cancer have been filed in the proceeding. Court records indicate that the number of claims have increased by nearly 100 since the JPML issued its last update in December. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452)
“Our Firm has heard from numerous individuals who were treated with diabetes drugs like Byetta and allegedly developed pancreatic cancer, pancreatitis or thyroid cancer due to their use. It is not surprising that the number of claims filed in the multidistrict litigation has grown so quickly,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free case evaluations to patients who took Byetta and were diagnosed with pancreatic cancer, thyroid cancer or pancreatitis.
Byetta Pancreatic Cancer Allegations
According to court documents, all of the lawsuits pending in the Southern District of California allege that Byetta and similar diabetes drugs, including Januvia and Victoza, are associated with an increased risk of pancreatic cancer. The multidistrict litigation was established by the JPML in August 2013, when only 53 such claims were pending in federal courts around the country. According to an Order issued in November, the litigation’s “Science Days” have been scheduled for February 4th and 5th, at which time the Court will receive an account of the scientific matters relevant to Byetta lawsuits and other claims pending in the proceeding. Matters to be addressed include the role of drug therapy in treating diabetes; information relating to the impact incretin mimetics on the pancreas; and information concerning pancreatic cancer.
Product liability claims involving incretin mimetics began to mount in March 2013, when the U.S. Food & Drug Administration (FDA) began to investigate a potential link between drugs like Byetta and pancreatic cancer. The FDA launched the review after a small study indicated that incretin mimetics might cause precancerous changes to the cells of the pancreas. Though the FDA has so far been unable to conclude that such an association does exist, its review is ongoing.
In April 2013, the Institute for Safe Medicine Practices reported that in a single 12-month period, the FDA had received 263 reports of pancreatitis, 71 cases of pancreatic cancer, and 14 incidents of thyroid cancer among patients taking Byetta. The same review also found that incretin mimetics were far more likely to be associated with pancreatic cancer than other classes of diabetes drugs.*
Alleged victims of Byetta and pancreatic cancer, as well as thyroid cancer and pancreatitis, may be entitled to financial compensation for their injury-related damages. To learn more about filing a Byetta lawsuit, please visit Bernstein Liebhard LLP’s website. For a free legal review, please call 800-511-5092.
*ismp.org/quarterwatch/pdfs/2012Q3.pdf, ISMP, April 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com